Here, we report FLT3 as a therapeutic target of CML that activates FLT3-JAK/STAT3-TAZ-TEAD-CD36 pathway during BP progression and promotes the acquisition of BCR::ABL1 TKI resistance in BP-CML patients. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.